FDA REFORM INDUSTRY CONSENSUS DOCUMENT INCLUDES TWO 510(K) REVIEW OPTIONS; MANUFACTURERS OTHERWISE UNIFIED AS CONGRESS FINALIZES REFORM MEASURES
This article was originally published in The Gray Sheet
Executive Summary
A consensus FDA reform proposal released by major device industry associations Oct. 13 suggests two alternative paths to ensuring that 510(k) devices can be marketed within 90 days after submitting a premarket notification. The relatively minor differences of opinion on changes to 510(k) requirements represent the only division in what is otherwise a unified industry front on the legislative proposal.
You may also be interested in...
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.